Equity Overview
Price & Market Data
Price: $9.86
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,545,162,880
Daily Volume: 0
Performance Metrics
1 Week: -18.01%
1 Month: -23.64%
3 Months: -19.55%
6 Months: -19.75%
1 Year: 10.98%
YTD: -23.66%
Details
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.